

Health Care Market Oversight

Option Care Merger with Amedisys

The [Health Care Market Oversight](#) (HCMO) program reviews health care business deals to make sure they support statewide goals related to cost, equity, access, and quality. After finishing a review, the Oregon Health Authority (OHA) decides whether a business deal, or transaction, should proceed. On June 20, 2023 OHA accepted a complete [notice](#) from Option Care Health, Inc. describing plans to merge with Amedisys, Inc.

Who's involved?

Option Care Health, Inc. ("Option Care") is a publicly traded corporation based in Bannockburn, IL, that provides infusion therapy services nationwide. Option Care clinicians dispense and administer medication intravenously to patients in the home and at infusion suites to treat chronic and complex medical conditions including cancer, infectious diseases, and inflammatory disorders. Option Care operates two locations in Oregon (Portland and Bend) which together serve approximately 3,400 patients annually.

Amedisys, Inc. ("Amedisys") is a publicly traded corporation headquartered in Baton Rouge, LA. Amedisys provides in-home care services including home health, hospice, and palliative care across 38 states. In Oregon, Amedisys operates three home health agencies (Salem, Portland, and Roseburg) and one hospice agency located in Roseburg. Amedisys currently serves approximately 5,200 home health patients and 500 hospice patients in Oregon annually.

About the deal

Through this business deal, Amedisys will become a wholly owned subsidiary of Option Care. Option Care and Amedisys intend to continue providing existing home health, hospice, and infusion services in Oregon and are not planning any changes in Oregon personnel or insurance contracts in connection with the deal. They expect to maintain existing service locations and continue serving Oregon Health Plan, Medicare, and commercially insured patients. Option Care says the deal will help the companies serve more home health, hospice, and home infusion patients across Oregon and provide more coordinated care to patients who need multiple services.

What's next?

OHA will conduct a 30-day review of the deal to understand how it could affect the cost and quality of health care, access to services, and health equity. During the review, OHA will use health care data, news and media reports, information from the companies, and input from the public to decide whether the deal should be approved.

We want to hear from you!

Public input is crucial to OHA's review! Your feedback can help us understand how this business deal could help or harm people in your community. To share your thoughts and feedback, please email hcmo.info@oha.oregon.gov by **July 5, 2023**. In your email, include the word "Option Care", what you think, and whether you support or oppose the deal.

You can get this document in other languages, large print, braille, or a format you prefer free of charge. Contact us by email at hcmo.info@oha.oregon.gov or by phone at 503-385-5948. We accept all relay calls.